Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

BK080058 Letter

November 25, 2008

CaridianBCT, Inc.
Attention: Ms. Isabel McGann
10811 W. Collins Avenue
Lakewood, CO  80215-4498

Re:                      BK080058
Product:               Trima Accel® Automated Blood Component Collection System
Date Received:      27-OCT-08
Classification:        II
Device Code:         GKT

Dear Ms. McGann:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act.  The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device has been classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls.  Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898.  In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.  You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.  This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification.  The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice on promotional labeling and advertisement for your device, please contact our Advertising and Promotional Labeling Staff (HFM-602) at (301) 827-3028.  Also, please note the regulation entitled, ²Misbranding by reference to premarket notification² (21CFR Part 807.97).  You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 835-4709 or (301) 827-1800 or at its Internet address:

Sincerely yours,


Basil Golding, M.D.
Division of Hematology 
Office of Blood Research and Review
Center for Biologics Evaluation and Research                 


Indications for Use                                


510(k) Number: BK080058                             

Device Name: Trima Accel® Automated Blood Component Collection System

Indications For Use:


The Trima Accel system is an automated blood cell separator intended for use in collecting blood components for later transfusion into patients.  

Depending on the disposable tubing set used, the Trima Accel system may collect the following products alone or in combination depending on the approval of the disposable tubing set:

  • Platelets Pheresis (single, double, or triple units)
  • Platelets Pheresis, Leukocytes Reduced (single, double, or triple units)
  • Plasma
  • Plasma, Leukocytes Reduced
  • AS-3 Red Blood Cells (single or double units)
  • AS-3 Red Blood Cells, Leukocytes Reduced (single or double units) utilizing an integrated filter

The Trima Blood Component Sampling Accessory, which is either integrated into the disposable tubing sets or as a dockable stand alone, is intended to allow aseptic removal of a sample from the platelet bag for subsequent bacterial or other applicable testing.  The Sampling Accessory does not have contact with blood fluids that are reinfused to a donor or patient.

Page Last Updated: 10/01/2009
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English